RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.
8 Jan, 2022 | 23:07h | UTCDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London
Commentaries on Twitter
Dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART. https://t.co/PP0XaEVswO pic.twitter.com/pQvhjdXcUk
— NEJM (@NEJM) December 29, 2021
Visual Abstract: Dolutegravir as First- or Second-Line HIV Treatment in Children https://t.co/2RIg9uH2V1 pic.twitter.com/mDr1Z6l6CJ
— NEJM (@NEJM) January 4, 2022